On April 13, 2026 Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 in San Diego, California. The presentations highlight Leukogene’s MHC class II engager lead development candidates in acute myeloid leukemia (AML) and pancreatic cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first poster is titled "MHC class II engager immunotherapy for the treatment of acute myeloid leukemia (Poster Board #24, Poster #5552)".
The second poster is titled "MHC class II targeted immunotherapy in the treatment of pancreatic cancer (Poster Board #23, Poster #5551)".
These presentations will focus on an MHC class II-directed strategy in hematological cancers and solid tumors designed to recruit and activate anti-tumor immune cells, with the goal of converting immunologically "cold" tumors into more inflamed, "hot" lesions that respond better to immunotherapy. The company has developed a robust preclinical data package with evidence of single agent and combination efficacy, underscoring the potential of this approach to address a major unmet need in aggressive malignancies.
Both posters will be presented during the Immunology poster session titled "Bi- and Tri-Specific Antibody Therapies" on April 21, 2026, from 2:00 p.m. to 5:00 p.m. Pacific Time in Poster Section 6 at the San Diego Convention Center.
"Acute myeloid leukemia and pancreatic cancer remain among the most lethal and treatment‑resistant cancers, and there is a pressing need for more effective and durable therapies," said Sandeep Gupta, Ph.D., Chief Executive Officer of Leukogene Therapeutics. "These AACR (Free AACR Whitepaper) presentations emphasize the potential of our MHC class II-engager platform to reshape immune responses in both hematologic and solid tumors, and they represent an important step toward bringing new immunotherapy options to patients with limited choices."
(Press release, Leukogene Therapeutics, APR 13, 2026, View Source [SID1234664339])